Research graph
References from ACG Clinical Guideline: Preventive Care for Patients With Cirrhosis. Local targets link to admitted publications; unresolved targets remain external evidence.
Diagnosis and management of cirrhosis and its complications: A review
10.1001/jama.2023.5997 · 2023 · External reference
Meaningful differences in patient-reported outcome measurement scores in liver disease
10.1097/hc9.0000000000000727 · 2025 · External reference
Pain in chronic liver disease compared to other chronic conditions: Results from a contemporary nationally representative cohort study
10.1097/hc9.0000000000000605 · 2025 · External reference
Sexual health and function in liver disease
10.1097/hc9.0000000000000691 · 2025 · External reference
Depression and anxiety management in cirrhosis
10.1097/hc9.0000000000000600 · 2025 · External reference
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
10.1016/j.jclinepi.2010.04.026 · 2011 · External reference
GRADE guidelines: 15. Going from evidence to recommendation—Determinants of a recommendation's direction and strength
10.1016/j.jclinepi.2013.02.003 · 2013 · External reference
GRADE guidelines: 3. Rating the quality of evidence
10.1016/j.jclinepi.2010.07.015 · 2011 · External reference
The AGA institute process for developing clinical practice guidelines part one: Grading the evidence
10.1016/j.cgh.2013.02.001 · 2013 · External reference
ACG clinical guideline: Hepatic encephalopathy
10.14309/ajg.0000000000003899 · 2026 · External reference
Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: An open labeled randomized controlled trial of lactulose versus no lactulose
10.1111/j.1440-1746.2012.07186.x · 2012 · External reference
A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy
10.1097/meg.0b013e32834696f5 · 2011 · External reference
Rifaximin treatment in hepatic encephalopathy
10.1056/nejmoa0907893 · 2010 · External reference
Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence
10.1097/hc9.0000000000000436 · 2024 · External reference
Rifaximin reduces rehospitalization risk in patients with cirrhosis and overt hepatic encephalopathy
10.1097/hc9.0000000000000874 · 2026 · External reference
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis
2023 · External reference
Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial)
10.1038/ajg.2010.455 · 2011 · External reference
Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy
10.1053/j.gastro.2010.08.061 · 2011 · External reference
Comparative efficacy of treatment options for minimal hepatic encephalopathy: A systematic review and network meta-analysis
10.1016/j.cgh.2019.08.047 · 2020 · External reference
Opportunities for improvement in the contemporary management of acute variceal hemorrhage: A systematic review of observational studies
10.1016/j.cgh.2017.02.018 · 2017 · External reference
Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades
10.1016/j.gie.2025.04.045 · 2025 · External reference
Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed
10.1002/hep.23045 · 2009 · External reference
Comparison of therapies for primary prevention of esophageal variceal bleeding: A systematic review and network meta-analysis
10.1002/hep.30220 · 2019 · External reference
Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding
2010 · External reference
Antimicrobial prophylaxis in decompensated cirrhosis: Friend or foe?
10.1097/hc9.0000000000000228 · 2023 · External reference
The impact of multidrug-resistant microorganisms on critically ill patients with cirrhosis in the intensive care unit: A cohort study
10.1097/hc9.0000000000000038 · 2023 · External reference
A randomized study of ceftriaxone for the prevention of infections in hospitalized patients with advanced cirrhosis
10.1097/hc9.0000000000000356 · 2024 · External reference
Antibiotic prophylaxis to prevent infection in patients with Child–Pugh A cirrhosis with upper gastrointestinal bleed: An open label randomised controlled trial
10.1007/s12072-024-10767-2 · 2025 · External reference
Electronic interventions to improve quality for inpatient cirrhosis care: A prospective evaluation
10.14309/ajg.0000000000003334 · 2025 · External reference
Prophylactic antibiotics for upper gastrointestinal bleeding in patients with cirrhosis: A systematic review and Bayesian meta-analysis
10.1001/jamainternmed.2025.3832 · 2025 · External reference
Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites
10.1016/j.jhep.2017.02.005 · 2017 · External reference
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis
10.1016/j.jhep.2022.05.021 · 2022 · External reference
Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial
10.1097/hep.0000000000000342 · 2023 · External reference
Baveno VII: Renewing consensus in portal hypertension
10.1016/j.jhep.2021.12.022 · 2022 · External reference
AASLD practice guideline on noninvasive liver disease assessment of portal hypertension
10.1097/hep.0000000000000844 · 2025 · External reference
Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives
10.1097/hc9.0000000000000682 · 2025 · External reference
A systematic review of noninvasive laboratory indices and elastography to predict hepatic decompensation
10.1097/hc9.0000000000000675 · 2025 · External reference
Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials
10.1002/hep.24786 · 2012 · External reference
Use of intravenous albumin: A guideline from the international collaboration for transfusion medicine guidelines
10.1016/j.chest.2024.02.049 · 2024 · External reference
Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis
2019 · External reference
Intravenous albumin after outpatient paracentesis reduces risk of AKI hospitalization: A national cohort study
10.1097/hep.0000000000001739 · 2026 · External reference
Albumin prevents kidney injury but is underutilized in a cohort of patients undergoing large-volume paracentesis
10.1097/hc9.0000000000000760 · 2025 · External reference
The global epidemiology of hepatocellular carcinoma
10.1097/hc9.0000000000000932 · 2026 · External reference
Risk-stratified surveillance for hepatocellular carcinoma
10.1097/hc9.0000000000000943 · 2026 · External reference
From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma
10.1097/hc9.0000000000000846 · 2025 · External reference
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis
10.1016/j.jhep.2022.01.023 · 2022 · External reference
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival
10.1016/j.jhep.2010.03.010 · 2010 · External reference
Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities
10.1002/hep.24545 · 2011 · External reference
Randomized controlled trial of screening for hepatocellular carcinoma
10.1007/s00432-004-0552-0 · 2004 · External reference
Benefits and harms of hepatocellular carcinoma screening outreach in patients with cirrhosis: A multicenter randomized clinical trial
10.1093/jnci/djae228 · 2025 · External reference
Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis
10.1053/j.gastro.2018.01.064 · 2018 · External reference
Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification
10.1097/hc9.0000000000000915 · 2026 · External reference
Performance of the multi-target hepatocellular carcinoma blood test: Design and rationale of the ALTUS study
10.1097/hc9.0000000000000800 · 2025 · External reference
Abbreviated gadoxetic acid–enhanced MRI versus ultrasonography for HCC surveillance in high-risk patients: A randomized trial protocol
10.1097/hc9.0000000000000839 · 2025 · External reference
National liver cancer screening trial (TRACER) study protocol
10.1097/hc9.0000000000000565 · 2024 · External reference
Educational, financial, logistical, emotional, and social needs among patients with hepatocellular carcinoma
10.1097/hc9.0000000000000739 · 2025 · External reference
The impact of BCLC recommendations on survival for patients with hepatocellular carcinoma
10.1097/hc9.0000000000000750 · 2025 · External reference
Quality of care in hepatocellular carcinoma—A critical review
10.1097/hc9.0000000000000595 · 2025 · External reference
HCC surveillance in hepatitis C: A longitudinal algorithm improves alpha-fetoprotein screening
10.1097/hc9.0000000000000719 · 2025 · External reference
Chemoprevention of hepatocellular carcinoma
10.1097/hc9.0000000000000836 · 2025 · External reference
Systematic review with meta-analysis: The effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma
10.1111/apt.16515 · 2021 · External reference
Aspirin use is associated with a reduced incidence of hepatocellular carcinoma: A systematic review and meta-analysis
10.1002/hep4.1640 · 2021 · External reference
Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: A systematic review and dose–response meta-analysis
10.1136/bmjopen-2016-013739 · 2017 · External reference
AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
10.1097/hep.0000000000000466 · 2023 · External reference
The effect of aspirin use on incident hepatocellular carcinoma: An updated systematic review and meta-analysis
10.3390/cancers15133518 · 2023 · External reference
Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: Nationwide emulated trials
10.1097/hc9.0000000000000013 · 2023 · External reference
How to improve care in outpatients with cirrhosis and ascites: A new model of care coordination by consultant hepatologists
10.1016/j.jhep.2013.03.010 · 2013 · External reference
Alcohol rehabilitation within 30 days of hospital discharge is associated with reduced readmission, relapse, and death in patients with alcoholic hepatitis
10.1016/j.cgh.2019.04.048 · 2020 · External reference
Hospitalization and mortality due to hepatitis A in Taiwan: A 15-year nationwide cohort study
10.1111/jvh.12564 · 2016 · External reference
Immunizations in chronic liver disease: What should be done and what is the evidence
10.1007/s11894-012-0300-6 · 2013 · External reference
Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
10.1056/nejm199801293380503 · 1998 · External reference
Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma
10.1111/apt.17120 · 2022 · External reference
Seroprevalence of hepatitis A, B, and C viruses in Turkish alcoholic cirrhotics and the impact of hepatitis B on clinical profile
10.3855/jidc.6002 · 2015 · External reference
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study
10.1002/1097-0142(19941101)74:9<2442::aid-cncr2820740909>3.0.co;2-# · 1994 · External reference
Current impact of viral hepatitis on liver cancer development: The challenge remains
10.3748/wjg.v27.i24.3556 · 2021 · External reference
Low level of hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in compensated cirrhotic patients
10.4254/wjh.v16.i11.1321 · 2024 · External reference
Predicting the onset of hepatitis B virus-related acute-on-chronic liver failure
10.1016/j.cgh.2022.03.016 · 2023 · External reference
Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure
10.1016/j.jhep.2021.05.026 · 2021 · External reference
Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
10.1016/j.jhep.2014.08.010 · 2014 · External reference
Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: An open-label randomised clinical trial
10.1136/gutjnl-2022-328222 · 2023 · External reference
Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease
10.1053/jlts.2001.23069 · 2001 · External reference
Response to hepatitis B vaccination in patients with liver cirrhosis
10.1002/rmv.1942 · 2017 · External reference
Two-dose hepatitis B vaccine (heplisav-B) results in better seroconversion than three-dose vaccine (engerix-B) in chronic liver disease
10.1007/s10620-020-06437-6 · 2021 · External reference
Re-vaccination for hepatitis B in previous non-responders following hepatitis C eradication
10.1093/infdis/jiad301 · 2024 · External reference
Clinical impact of influenza immunization in patients with liver cirrhosis
10.1016/j.jcv.2007.04.018 · 2007 · External reference
Effectiveness of influenza vaccines in adults with chronic liver disease: A systematic review and meta-analysis
10.1136/bmjopen-2019-031070 · 2019 · External reference
Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults
10.1056/nejmoa2213836 · 2023 · External reference
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study
10.1016/j.jhep.2020.09.024 · 2021 · External reference
The global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis
10.1097/hc9.0000000000000689 · 2025 · External reference
Association of BNT162b2 mRNA and mRNA-1273 vaccines with COVID-19 infection and hospitalization among patients with cirrhosis
10.1001/jamainternmed.2021.4325 · 2021 · External reference
SARS-CoV-2 infections among patients with liver disease and liver transplantation who received COVID-19 vaccination
10.1002/hep4.1853 · 2022 · External reference
Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis
10.1002/hep.32337 · 2022 · External reference
Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: A systematic review with meta-analysis of 51,834 patients
10.1080/08998280.2023.2165344 · 2023 · External reference
Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study
10.1002/hep.32780 · 2023 · External reference
Poor emotional well-being and energy are associated with mortality in patients with advanced liver failure
10.1097/hc9.0000000000000529 · 2024 · External reference
Integrative hepatology: Enhancing overall health to manage liver disease
2025 · External reference
The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease
10.1097/hc9.0000000000000352 · 2024 · External reference
Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis
10.1002/hep.31042 · 2020 · External reference
Simultaneous management of alcohol use disorder and liver disease: A systematic review and meta-analysis
10.1097/adm.0000000000001084 · 2023 · External reference
Hepatology consultation is associated with decreased early return to alcohol use after discharge from an inpatient alcohol use disorder treatment program
10.1097/hc9.0000000000000414 · 2024 · External reference
Integrating hepatology with addiction care for inpatients with alcohol use disorder reduces future liver-related events
10.1097/hc9.0000000000000780 · 2025 · External reference
The impact of integrated care on clinical outcomes in patients with alcohol-associated liver disease: Early outcomes from a multidisciplinary clinic
10.1097/hc9.0000000000000603 · 2025 · External reference
Brief alcohol interventions are underutilized in persons with nonalcohol-associated chronic liver diseases
10.1097/hc9.0000000000000420 · 2024 · External reference
How effective are brief interventions in reducing alcohol consumption: Do the setting, practitioner group and content matter? Findings from a systematic review and metaregression analysis
10.1136/bmjopen-2016-011473 · 2016 · External reference
Treatment of alcohol use disorder in alcohol-associated liver disease: A meta-analysis
10.1097/hc9.0000000000000686 · 2025 · External reference
Treatment interventions to maintain abstinence from alcohol in primary care: Systematic review and network meta-analysis
10.1136/bmj.m3934 · 2020 · External reference
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial
10.1001/jama.293.13.1617 · 2005 · External reference
Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics
10.1111/j.1530-0277.2007.00593.x · 2008 · External reference
Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: A randomized 12-month trial
10.1002/hep.22367 · 2008 · External reference
Diet composition impacts the natural history of steatotic liver disease
10.1097/hc9.0000000000000754 · 2025 · External reference
Skeletal muscle and MASLD: Mechanistic and clinical insights
10.1097/hc9.0000000000000711 · 2025 · External reference
Mediterranean diet and associated metabolite signatures in relation to MASLD progression: A prospective cohort study
10.1097/hc9.0000000000000791 · 2025 · External reference
Home-based intensive nutrition therapy improves frailty and sarcopenia in patients with decompensated cirrhosis: A randomized clinical trial
10.1111/jgh.16035 · 2023 · External reference
Outpatient intensive nutrition therapy improves survival and frailty in males with alcohol-related ACLF-randomized controlled trial
10.1016/j.cgh.2024.09.021 · 2025 · External reference
Branched-chain amino acids supplementation improves liver frailty index in frail compensated cirrhotic patients: A randomized controlled trial
10.1186/s12876-023-02789-1 · 2023 · External reference
Branched-chain amino acid supplementation does not improve measures of sarcopenia in cirrhosis: Results of a randomised controlled trial
10.1111/apt.17917 · 2024 · External reference
Reversing malnutrition and low muscle strength with targeted enteral feeding in patients awaiting liver transplant: A randomized controlled trial
10.1097/hep.0000000000000840 · 2024 · External reference
Exercise and nutrition interventions for sarcopenia in cirrhosis: A systematic review and network meta-analysis of randomized controlled trials
10.1038/s41430-025-01642-w · 2025 · External reference
Aerobic exercise interventions lead to MASH resolution in clinical trials: Pooled analysis using the MASH resolution index
10.1097/hc9.0000000000000681 · 2025 · External reference
Home exercise, branched-chain amino acids, and probiotics improve frailty in cirrhosis: A randomized clinical trial
10.1097/hc9.0000000000000443 · 2024 · External reference
The impact of sarcopenia and frailty on decompensation in compensated cirrhosis: A systematic review
10.1097/hc9.0000000000000811 · 2025 · External reference
Exercise training for liver transplant candidates
10.1016/j.transproceed.2019.08.045 · 2019 · External reference
Low daily step count is associated with a high risk of hospital admission and death in community-dwelling patients with cirrhosis
10.1016/j.cgh.2022.03.012 · 2022 · External reference
Prevalence and outcomes of steatotic liver disease subtypes in older adults
10.1097/hc9.0000000000000756 · 2025 · External reference
The impact of aging on liver health and the development of liver diseases
10.1097/hc9.0000000000000808 · 2025 · External reference
Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: A meta-analysis of randomized controlled trials
10.1007/s00535-023-02060-0 · 2024 · External reference
Exercise training as an intervention for frailty in cirrhotic patients on the liver transplant waiting list: A systematic review
10.4254/wjh.v15.i10.1153 · 2023 · External reference
Outcomes of exercise interventions in patients with advanced liver disease: A systematic review of randomized clinical trials
10.14309/ajg.0000000000001883 · 2022 · External reference
Home-based physical activity and diet intervention to improve physical function in advanced liver disease: A randomized pilot trial
10.1007/s10620-019-06034-2 · 2020 · External reference
Exercise training is safe and feasible in patients awaiting liver transplantation: A pilot randomized controlled trial
10.1002/lt.25616 · 2019 · External reference
A multicenter pilot randomized clinical trial of a home-based exercise program for patients with cirrhosis: The Strength Training Intervention (STRIVE)
10.14309/ajg.0000000000001113 · 2021 · External reference
Effects of an exercise programme on functional capacity, body composition and risk of falls in patients with cirrhosis: A randomized clinical trial
10.1371/journal.pone.0151652 · 2016 · External reference
Home exercise training improves exercise capacity in cirrhosis patients: Role of exercise adherence
10.1038/s41598-017-18320-y · 2018 · External reference
Smoking aggravates inflammation, fibrogenesis, angiogenesis and cancer risk in patients with cirrhosis
10.1111/liv.70314 · 2025 · External reference
Cause-specific mortality among patients with cirrhosis in a population-based cohort study in Ontario (2000–2017)
10.1097/hc9.0000000000000194 · 2023 · External reference
Effect of combined tobacco use and type 2 diabetes mellitus on prevalent fibrosis in patients with MASLD
10.1097/hc9.0000000000000300 · 2023 · External reference
Cigarette smoking and liver diseases
10.1016/j.jhep.2022.01.016 · 2022 · External reference
Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project
10.1038/s41416-018-0007-z · 2018 · External reference
Effect of smoking on survival of patients with hepatocellular carcinoma
10.1111/liv.13466 · 2017 · External reference
Smoking and risk of liver cirrhosis: A population-based cohort study
10.3109/00365521.2013.777469 · 2013 · External reference
Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer
10.1093/ije/dyp280 · 2009 · External reference
Association between smoking, smoking cessation, and mortality by race, ethnicity, and sex among US adults
10.1001/jamanetworkopen.2022.31480 · 2022 · External reference
Active smoking before liver transplantation in patients with alcohol use disorder: Risk factors and outcomes
10.3390/jcm9092710 · 2020 · External reference
Effects of smoking on survival for patients with end-stage liver disease
10.1016/j.jamcollsurg.2009.01.050 · 2009 · External reference
Prevalent osteoporosis and fracture risk in patients with hepatic cirrhosis: A systematic review and meta-analysis
10.1186/s12876-025-03720-6 · 2025 · External reference
Low screening rates and high prevalence of osteoporosis in cirrhosis: A real-world retrospective analysis
10.1111/apt.17823 · 2024 · External reference
Two-year risedronate treatment for osteoporosis in patients with esophageal varices: A non-randomized clinical trial
10.1007/s12072-022-10366-z · 2022 · External reference
Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial
10.1111/apt.18127 · 2024 · External reference
Causes of death in people with liver cirrhosis in England compared with the general population: A population-based cohort study
10.1038/ajg.2015.191 · 2015 · External reference
Increased risk for malignant neoplasms among patients with cirrhosis
10.1016/j.cgh.2010.10.014 · 2011 · External reference
Hepatic and extrahepatic cancer in cirrhosis: A longitudinal cohort study
10.1038/ajg.2010.477 · 2011 · External reference
An electronic decision support intervention reduces readmissions for patients with cirrhosis
10.14309/ajg.0000000000001608 · 2022 · External reference
The future of quality improvement for cirrhosis
10.1002/lt.26079 · 2021 · External reference
